Scheme S1. Synthesis of Fmoc-β 3 -Et-OH.
. β-Peptide sequences were validated by MALDI-TOF with α-cyano-4hydroxycinnamic acid. Figure S1 . Analytical RP-HPLC profiles to measure retention time of 14-helical β-peptides. Figure S2 . The plots of concentration-dependent growth inhibition of C. albicans by β-peptides. C. albicans cells (10 3 cells/mL) were incubated with β-peptides for 48 h and β-peptide susceptibility was assessed using an XTT reduction assay to compare the absorbance at 490 nm for β-peptide-treated samples and untreated samples. Data points are the average of three independent experiments of three replicates each. The arrow indicates the MIC value. Figure S3 . The concentration-dependent hemolysis of human red blood cells by β-peptides. βpeptides were incubated with human red blood cells for 1 h, and the absorbance of the supernatant was measured at 405 nm to calculate the percent of red blood cells lysed. 100% hemolysis was determined using a melittin control. Error bars denote standard deviation (n=3). The arrow indicates the hemolysis at the β-peptide MIC. (Figure 1a and 1d, X) . MIC (c) and hemolysis at the MIC (d) were affected by hydrophobic side chain variations (Figure 1a and 1d, Y) . MIC (e) and hemolysis at the MIC (f) were affected by cationic residue variation (Figure 1a and 1d, Z) . Error bars denote standard deviation (n=3). Sequences corresponding to the peptide numbers are provided in Figure 1 . Arrows link peptides with a one β-amino acid difference. 
